HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dewi Vernerey Selected Research

Squamous Cell Carcinoma (Epidermoid Carcinoma)

1/2022Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
9/2020Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials.
4/2020Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
1/2020Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
1/2018Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dewi Vernerey Research Topics

Disease

16Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 03/2015
13Neoplasms (Cancer)
01/2022 - 03/2015
9Colonic Neoplasms (Colon Cancer)
10/2021 - 12/2015
7Adenocarcinoma
01/2022 - 10/2017
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 01/2018
5Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 12/2019
4Microsatellite Instability
01/2021 - 07/2016
3Neoplasm Metastasis (Metastasis)
01/2022 - 12/2019
3Biliary Tract Neoplasms (Biliary Tract Cancer)
12/2020 - 12/2014
3Rectal Neoplasms (Rectal Cancer)
05/2020 - 12/2005
3Inflammation (Inflammations)
12/2014 - 08/2013
2Carcinoma (Carcinomatosis)
01/2021 - 06/2020
2Disease Progression
11/2020 - 11/2015
2Renal Cell Carcinoma (Grawitz Tumor)
02/2019 - 04/2018
2Pain (Aches)
06/2017 - 07/2016
2Fibrosis (Cirrhosis)
01/2016 - 02/2015
2Asthenia
11/2015 - 12/2014
1Dihydropyrimidine Dehydrogenase Deficiency
01/2021
1Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer)
11/2020
1Margins of Excision
05/2020
1Rare Diseases (Rare Disease)
04/2020
1Stomach Neoplasms (Stomach Cancer)
04/2020
1Turcot syndrome
04/2020
1Lung Neoplasms (Lung Cancer)
01/2019
1Kidney Neoplasms (Kidney Cancer)
04/2018
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2018
1Breast Neoplasms (Breast Cancer)
06/2017
1Cardiotoxicity
06/2017
1Fatigue
06/2017
1Atrophy
01/2016
1Exanthema (Rash)
11/2015
1Endarteritis
08/2015
1Arteriosclerosis
08/2015

Drug/Important Bio-Agent (IBA)

12Fluorouracil (Carac)FDA LinkGeneric
01/2022 - 12/2015
10Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2021 - 12/2014
7Cisplatin (Platino)FDA LinkGeneric
01/2022 - 12/2014
5Docetaxel (Taxotere)FDA Link
01/2022 - 01/2018
4Immune Checkpoint InhibitorsIBA
01/2022 - 04/2020
4Leucovorin (Folinic Acid)FDA Link
11/2020 - 12/2015
4folfirinoxIBA
11/2020 - 12/2019
3regorafenibIBA
01/2022 - 01/2021
3Circulating Tumor DNAIBA
10/2021 - 07/2019
3PlatinumIBA
01/2021 - 06/2020
3Irinotecan (Camptosar)FDA LinkGeneric
11/2020 - 12/2019
3Tyrosine Kinase InhibitorsIBA
02/2019 - 11/2015
2Trastuzumab (Herceptin)FDA Link
01/2022 - 06/2017
2Taxoids (Taxanes)IBA
01/2022 - 01/2021
2Biomarkers (Surrogate Marker)IBA
01/2021 - 03/2015
2IpilimumabIBA
11/2020 - 04/2020
2NivolumabIBA
11/2020 - 04/2020
2Telomerase (Telomerase Reverse Transcriptase)IBA
09/2020 - 01/2019
2Sunitinib (Sutent)FDA Link
02/2019 - 04/2018
2GemcitabineFDA Link
01/2019 - 12/2014
2Complement System Proteins (Complement)IBA
08/2015 - 09/2013
2AntibodiesIBA
08/2015 - 09/2013
1trifluridine tipiracil drug combinationIBA
01/2022
1B7-H1 AntigenIBA
01/2022
1Forkhead Transcription Factors (Forkhead Box Proteins)IBA
01/2022
1Thymidylate SynthaseIBA
01/2021
1Cell-Free Nucleic AcidsIBA
01/2021
1Paclitaxel (Taxol)FDA LinkGeneric
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1tremelimumabIBA
01/2021
1ErbB Receptors (EGF Receptor)IBA
01/2021
1raltitrexed (D 1694)IBA
01/2021
1durvalumabIBA
01/2021
1avelumabIBA
06/2020
1atezolizumabIBA
04/2020
1Calcibiotic Root Canal SealerIBA
01/2020
1afliberceptIBA
01/2020
1CarbohydratesIBA
12/2019
1AntigensIBA
12/2019
1pazopanibFDA Link
02/2019
1Carcinoembryonic AntigenIBA
01/2019
1Capecitabine (Xeloda)FDA Link
01/2018
1EpitopesIBA
01/2018
1Messenger RNA (mRNA)IBA
01/2018
1Immunoglobulins (Immunoglobulin)IBA
01/2018
1Epidermal Growth Factor (EGF)IBA
06/2017
1Biological ProductsIBA
11/2016
1Syndecan-1 (Syndecan 1)IBA
11/2016
1AlbuminsIBA
07/2016
1Immunoglobulin G (IgG)IBA
01/2016
1Dihydrotachysterol (AT 10)IBA
12/2015
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2015
1Monoclonal AntibodiesIBA
11/2015
1Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2015
1Bevacizumab (Avastin)FDA Link
11/2015
1Phenobarbital (Luminal)FDA Link
08/2015

Therapy/Procedure

22Drug Therapy (Chemotherapy)
01/2022 - 12/2014
8Therapeutics
01/2022 - 11/2015
8Adjuvant Chemotherapy
10/2021 - 12/2015
3Duration of Therapy
10/2021 - 01/2018
3Chemoradiotherapy
01/2021 - 05/2020
3Radiotherapy
01/2021 - 06/2017
3Immunotherapy
06/2020 - 11/2019
2Induction Chemotherapy
01/2021 - 11/2020
2Neoadjuvant Therapy
04/2020 - 11/2019
1Pelvic Exenteration
10/2020
1Combination Drug Therapy (Combination Chemotherapy)
06/2020